Compare STXS & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STXS | NYXH |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.6M | 190.6M |
| IPO Year | 2004 | 2021 |
| Metric | STXS | NYXH |
|---|---|---|
| Price | $2.09 | $3.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $4.00 | ★ $11.67 |
| AVG Volume (30 Days) | ★ 405.1K | 55.5K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $29,346,617.00 | N/A |
| Revenue This Year | $24.21 | $97.32 |
| Revenue Next Year | $29.83 | $241.74 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.54 | $3.65 |
| 52 Week High | $3.59 | $11.87 |
| Indicator | STXS | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 33.29 |
| Support Level | $2.06 | N/A |
| Resistance Level | $2.49 | $5.02 |
| Average True Range (ATR) | 0.12 | 0.29 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 28.77 | 11.93 |
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.